Has Jeffrey Loomer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,860,539 in general payments to Jeffrey Loomer, MD across 1,571 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Loomer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Loomer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Loomer, MD

Rheumatology · Tucson, AZNPI 1003824442

Payments from drug & device makers

$1,860,539in general payments, 2019–2025

Across 1,571 payments — averaging $1184.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$579K
GSK$416K
Amgen$223K
UCB SA$194K
AbbVie$128K
Janssen Research & Development, LLC$96K
plus $225K from 40 others

$31in research payments, 2019–2025

Across 1 payment — averaging $30.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$31

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	32	$578,636
GSK	268	$415,559
Amgen(2 entities)	322	$222,969
UCB SA	44	$194,248
AbbVie	202	$128,305
Janssen Research & Development, LLC	57	$95,909
Gilead	50	$89,136
Takeda Pharmaceuticals U.S.A., Inc.	9	$43,169
Sanofi US Services Inc.	54	$35,563
Bristol Myers Squibb	14	$31,132
Regeneron	9	$15,400
UCB, Inc.	111	$2,574
Pfizer	102	$1,582
AstraZeneca(2 entities)	30	$905
E.r. Squibb & Sons, L.L.C.	39	$675
Lilly USA, LLC	28	$623
Johnson & Johnson(2 entities)	44	$619
Novartis	24	$544
Radius Health, Inc.	23	$510
Organon	20	$378
Genentech USA, Inc.	15	$373
Sanofi	13	$319
Boehringer Ingelheim	12	$253
Octapharma USA, Inc.	3	$119
Mallinckrodt Hospital Products Inc.	4	$100
Sobi, Inc	4	$98
Bioventus LLC	4	$89
Pacira Therapeutics, Inc.	4	$83
Janssen Scientific Affairs, LLC	1	$80
Aurinia Pharma U.S., Inc.	3	$62
Fresenius Kabi USA, LLC	2	$60
Kyowa Kirin, Inc.	2	$57
Mallinckrodt Enterprises LLC	3	$54
Ferring Pharmaceuticals Inc.	3	$46
Almatica Pharma LLC	2	$46
Sandoz	2	$42
Mylan Institutional Inc.	2	$41
Teva Pharmaceuticals USA, Inc.	2	$29
United Therapeutics Corporation	1	$25
Celltrion USA Inc.	1	$22
Actelion Pharmaceuticals US, Inc.	1	$21
ANI Pharmaceuticals, Inc.	1	$18
Kiniksa Pharmaceuticals, Ltd.	1	$18
Hikma Pharmaceuticals USA	1	$18
Abbott	1	$17
Ultragenyx Pharmaceutical Inc.	1	$16

How this compares

$1,860,539 in reported general payments places this provider in the 85th percentile of 102 rheumatology providers in Arizona.

See all rheumatology providers in Arizona →

Medicare billing

Part B allowed, 2024

$2,318,500

Medicare patients

664

Services billed

157,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Tucson

Romy CabacunganTucson$464K
Jawad BilalTucson$185K
Chian KwohTucson$166K
Dominick SudanoTucson$145K
Barbara BodeTucson$111K
Michael MaricicTucson$110K
Augusto PosadasTucson$81K
Ernest VinaTucson$48K
Ulker TokTucson$20K
Jeffrey LisseTucson$13K

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →